ChatGPTを活用して業務のAI化を進めています。プロンプトエンジニアリングの専門家です！と、名乗れるレベルではありませんが、かなり色々使いこなしてきています。この１年、病気で失われた能力は、別な能力を発達させる、進化することで生き残っていこうと思います。
<><><>
23/11/04
[PDF] Pulmonologists' Perspectives on and Access to Palliative Care for Patients With Idiopathic Pulmonary Fibrosis in South Carolina
KO Lindell, M Madisetti, T Fasolino, MC Pittman… - Palliative Medicine Reports, 2023
… Idiopathic pulmonary fibrosis (IPF) is a serious illness with an unpredictable disease course and survival rates comparable with some cancers. Patients with IPF … Research Question: The purpose of this survey was to gain perspectives regarding …
- サウスカロライナ州の特発性肺線維症患者の緩和ケアに対する呼吸器科医の見解と緩和ケアへのアクセス
[PDF] Prediction and analysis of genetic effect in idiopathic pulmonary fibrosis and gastroesophageal reflux disease
P Chen, L Xie, L Ma, X Zhao, Y Chen, Z Ge - IET Systems Biology, 2023
… idiopathic pulmonary fibrosis (IPF) and gastroesophageal reflux disease (GERD), more and more studies have indicated that GERD is associated with IPF, … The aim of the present study is to identify and analyse the differentially expressed genes (DEGs) …
- 特発性肺線維症および胃食道逆流症における遺伝的影響の予測と解析
A 64-Year-Old Man With Back Spasms and Dyspnea 3 Weeks After Lung Transplant
J Lau
… His past medical history included end-stage idiopathic pulmonary fibrosis for which he had undergone left lung transplant 3 weeks earlier. Pathologic examination findings were consistent with usual interstitial pneumonia. The …
- 肺移植後 3 週間で背中のけいれんと呼吸困難を患った 64 歳の男性
A 59-Year-Old Man With Progressive Shortness of Breath and Fatigue 18 Months After Bilateral Lung Transplant
T Tarmey, AC Roden, CC Kennedy
… He had undergone bilateral lung transplant 18 months earlier for idiopathic pulmonaryfibrosis. His symptoms had been progressing slowly for the past year, and at presentation he had dyspnea on mild exertion (New York Heart Association …
- 両側肺移植後18か月で進行性の息切れと倦怠感を抱える59歳の男性
23/11/02
Osteopontin: an essential regulatory protein in idiopathic pulmonary fibrosis
X Zhu, J Ji, X Han - Journal of Molecular Histology, 2023
… Idiopathic pulmonary fibrosis (IPF) Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease with an unknown cause, classified as idiopathic interstitial pneumonia. The disease is characterized by the accumulation of fibroblasts in lung …
- オステオポンチン: 特発性肺線維症における必須の調節タンパク質
[PDF] Mass spectrometry-based autoimmune profiling reveals predictive autoantigens in idiopathic pulmonary fibrosis
G Leuschner, A Semenova, CH Mayr, TS Kapellos… - iScience, 2023
… In idiopathic pulmonary fibrosis (IPF), an incurable and fatal lung disease, diagnosis typically requires … of IPF and CTL-ILD patients over two disease progression time points. Our findings revealed significant upregulation of specific …
- 質量分析に基づく自己免疫プロファイリングにより、特発性肺線維症における予測的自己抗原が明らかに
Predicting factors of acute exacerbation of idiopathic pulmonary fibrosis
M Browarski, C Rousseau, P Chauvin, S Guillot… - 2023
… Background: Idiopathic pulmonary fibrosis(IPF) is a severe interstitial lung disease with a dramatically … IPF could develop acute exacerbation of IPF (AE-IPF) with an extremely bad prognosis. The objective of this study was to determine …
- 特発性肺線維症の急性増悪の予測因子
Preclinical idiopathic pulmonary fibrosis (IPF): a retrospective cohort study
T Bando, R Takei, J Fukihara, H Sasano, Y Yamano… - 2023
… Results: Of 419 IPF patients, 28 patients met the criteria for preclinical IPF (median age 68 yo, 27 males, KL-6 595 U/L, FVC 3.69 L (… IPF can progress to clinical IPF in several years and suggests that asymptomatic interstitial lung disease should not be …
- 前臨床特発性肺線維症（IPF）：後ろ向きコホート研究
Trajectories of health-related quality of life (HRQL) in patients with idiopathic pulmonary fibrosis (IPF)
A Olson, JL Todd, LD Snyder, P Li, ML Neely - 2023
… Aim: To evaluate trajectories of HRQL in a real-world cohort of patients with IPF. Methods: Patients with IPF that was diagnosed or confirmed at the enrolling centre in the previous 6 months were enrolled into the prospective IPF-PRO Registry at 46 …
- 特発性肺線維症（IPF）患者における健康関連の生活の質（HRQL）の軌跡
Nutritional Status in Idiopathic Pulmonary Fibrosis
EBC Cesar, ES Álvarez, RF Jiménez, FE Hernandez… - 2023
… Introduction In idiopathic pulmonaryfibrosis (IPF), Despite having a normal weight, due to an increase in fat, they … IPF through new techniques for a better diagnosis and intervention Material and methods A prospective, multicenter study has been …
- 特発性肺線維症における栄養状態
Artificial intelligence to detect pulmonary hypertension in idiopathic pulmonary fibrosis: Study design
A Arvanitaki, GP Diller, B Mukherjee, A Lawrence… - 2023
… reported in 8-15% of patients with idiopathicpulmonary fibrosis (IPF) upon initial work-up and is … , both to detect PH in IPF and to predict severe PH IPF that need referral for further work-up, … of deep learning (DL) models to diagnose and predict …
- 特発性肺線維症における肺高血圧症を検出する人工知能: 研究デザイン
CT-derived biomarkers as predictors of overall survival in patients with idiopathic pulmonary fibrosis (IPF)
F Bonella, L Salhöfer, M Meetschen, L Umutlu… - 2023
Background: Idiopathic pulmonary fibrosis(IPF) is the most common interstitial lung disease with a median survival time of 2.5 years without treatment. For this rare disease, there is still a lack of validated biomarkers for mortality risk assessment …
- 特発性肺線維症 (IPF) 患者の全生存期間の予測因子としての CT 由来のバイオマーカー
Relevance of the systematic sleep study on idiopathic pulmonary fibrosis (IPF)
JB Martinez, NS Oleo, VV Zygmunt, RB Aloy… - 2023
Introduction: Sleep breathing disorders (SBD) are a relevant comorbidity in IPF. Differences in SBD prevalence, features and impact may depend on the methodology used. We evaluated the SBD features and the treatment effect …
- 特発性肺線維症（IPF）に対する体系的な睡眠研究の関連性
Population pharmacokinetic (pop-PK) model of GB0139 as a tool to characterise the biomarker response in patients with idiopathic pulmonary fibrosis (IPF)
V Aslanis, D Schweinoch, A Mackinnon, N Hirani… - 2023
… ; while the IPF patient pop-PK model was trained on data from IPF patients receiving GB0139 … on Day 14, & plasma biomarkers pertinent to IPF. The relationship of the changes from BL in … Results: A sigmoidal relationship between …
- 特発性肺線維症 (IPF) 患者のバイオマーカー反応を特徴付けるツールとしての GB0139 の集団薬物動態 (pop-PK) モデル
23/10/31
[HTML] Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
F Bonella, P Spagnolo, C Ryerson - Drugs, 2023
… into the newest concepts of IPF pathogenesis and illustrate recent advances in pharmacological therapy for IPF, including new data and … Despite these and other clinical trials failing to identify a viable treatment of IPF, these studies have improved …
- 特発性肺線維症の現在および将来の治療状況
Uptake of Antifibrotics for Patients with Idiopathic Pulmonary Fibrosis: 2016-2022
DA Shankar, F Hawkins, KD Alysandratos, KC Wilson… - Annals of the American …, 2023
… followed by ≥2 subsequent ambulatory visits with an IPF diagnosis. Patients with another ILD or connective tissue disease prior to first IPFcode or medication initiation greater than 30 days prior to first IPF visit were excluded; our cohort …
- 特発性肺線維症患者に対する抗線維症の摂取：2016～2022年
[HTML] Real-World Clinical Efficacy of Antifibrotic Agents for Idiopathic Pulmonary Fibrosis: A Single-Center Retrospective Study in Japan
K Iwasaki, H Wakabayashi, A Saiki, H Ueshiba… - Drugs-Real World …, 2023
… The antifibrotic drugs, nintedanib and pirfenidone, inhibit the decline in forced vital capacity in patients with idiopathic pulmonaryfibrosis (IPF). … in forced vital capacity, survival period, causes of death, and risk factors for mortality in patients …
- 特発性肺線維症に対する抗線維化剤の実際の臨床効果：日本における単一施設の後ろ向き研究
Can biomarkers predict survival in idiopathic pulmonary fibrosis?
A Kayikci, F Alatas, H Yıldırım - 2023
… MATERIAL METHOD:Forty-seven patients diagnosed with IPF were included in the study. KL… is investigated in univariate Cox models in patients with IPF, it is seen that they were not a … biomarkers may contribute significantly to the …
- バイオマーカーは特発性肺線維症の生存を予測できるか?
Survival of idiopathic pulmonary fibrosis patients treated with antifibrotics versus lung transplantation
M Šterclová, M Zurkova, V Lostakova, M Plackova… - 2023
… Aim: To retrospectively analyze, if idiopathicpulmonary fibrosis (IPF) patients under 65 years at diagnosis, who fulfill criteria for LTx listing, … A included 67 IPF patients, who underwent LTx for IPF in 2000-2021. Cohort B included subjects from …
- 抗線維症治療と肺移植による特発性肺線維症患者の生存率
Experiences of individuals with Idiopathic Pulmonary Fibrosis (IPF) participating in Home-Based Pulmonary Rehabilitation (HBPR) in India: A Qualitative study
H Hanif, O Ahmed, J Manifield, M Shibli, Z Ahmed… - 2023
… Aim: To explore the experiences of people with IPF participating in a HBPR programme. Method: Individuals with IPF who have participated in a HBPR were … Conclusion: HBPR using a paper-based manual may be an acceptable mode of …
- インドで在宅肺リハビリテーション (HBPR) に参加した特発性肺線維症 (IPF) 患者の経験: 定性的研究
What Are The Factors Affecting Respiratory Muscle Functions in Idiopathic Pulmonary Fibrosis?: A Preliminary Study
ÖE Harputlu, Z Yasacı, T Tahmaz, GK Aslan, E Kıyan… - 2023
… Background: Respiratory work and respiratory oxygen consumption increase in IPF. Exertional dyspnea, the most prominent symptom of IPF, … Conclusion: Our results showed that exertional dyspnea and fatigue are related to respiratory muscle …
- 特発性肺線維症における呼吸筋機能に影響を与える要因は何か?: 予備研究
Idiopathic pulmonary fibrosis and progressive fibrotic interstitial lung disease
P Evans, E Rowlands, B Hope-Gill - Medicine
… of the idiopathic interstitial pneumonias is idiopathic pulmonary fibrosis (IPF), characterized by progressive lung fibrosis, lung function decline, symptom burden and early mortality. The precise aetiology of IPF … IPF is the most common of the …
- 特発性肺線維症および進行性線維性間質性肺疾患
Safety and tolerability of combination treatment with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: a systemic review and meta-analysis
J Lee, JU Song - Journal of Thoracic Disease
Safety and tolerability of combination treatment with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: a systemic review and meta-analysis - Lee - Journal of Thoracic Disease … Safety and tolerability of combination treatment …
- 特発性肺線維症患者におけるピルフェニドンとニンテダニブの併用療法の安全性と忍容性：全身レビューとメタアナリシス
Relationship between Air pollution in comunidad de madrid and the development of chronic respiratory failure in patients with idiopathic pulmonary fibrosis
PM Aguilar, LG Carrera, CM Aguilar, C Carpio… - 2023
Aim: The aim of our study was to evaluate the relationship between major urban pollutants and the development of chronic respiratory failure in patients with IPF. Materials and methods: The probability of presenting chronic respiratory failure was …
- マドリード市の大気汚染と特発性肺線維症患者における慢性呼吸不全の発症との関係
<><><>
特発性肺線維症( idiopathic pulmonary fibrosis (IPF) )関連の学術的情報収集してシェアしています。Google Scholar SearchのUpdateを定期的に掲載しています。GoogleのAIが一定の重み付けはしているとは思いますが、玉石混交です。
当面、毎週アラートの内容をアップしていこうと思います。
###
